Book a Meeting

Anti-ECSCR Antibody, Non-Fucosylated (BioBet-795ZP) (CAT#: BioBet-795ZP) Datasheet

Target
ECSCR
Isotype
IgG
Description
ADCC-Enhanced anti-ECSCR (1A7) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced ECSCR antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
ECSCR
Full Name
endothelial cell surface expressed chemotaxis and apoptosis regulator
Background
The protein encoded by this gene is primarily found in endothelial cells and blood vessels, where it is involved in cell shape changes and EGF-induced cell migration. It can enhance the activation of vascular endothelial growth factor receptor-2/kinase insert domain receptor and also promote the proteolysis of internalized kinase insert domain receptor. This gene may play a role in angiogenesis-related diseases. Alternative splicing results in multiple transcript variants.
Alternative Names
ECSCR; endothelial cell surface expressed chemotaxis and apoptosis regulator; ARIA; ECSM2; apoptosis regulator through modulating IAP expression; endothelial cell-specific molecule 2
Gene ID
641700
Cellular Localization
Plasma membrane
Function
Regulates endothelial chemotaxis and tube formation. Has a role in angiogenesis and apoptosis via modulation of the actin cytoskeleton and facilitation of proteasomal degradation of the apoptosis inhibitors BIRC3/IAP1 and BIRC2/IAP2.
Post-translational modifications
May be heavily O-glycosylated
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
1A7
Host
Human
Species Reactivity
Human
Description
They are antibody which bind ECSCR and inhibit chemotaxis. The antibody may bind an epitope QTVPPNSTTM on the extracellular domain of ECSCR. The antibody, which may be provided as a pharmaceutical composition, may be used to inhibit tumour cell invasion and may be used in the treatment of diseases, for example diseases associated with angiogenesis such as cancer.
Antibody Indication
Cancer

Cancer

Related Products

Anti-ECSCR Antibody, Non-Fucosylated (BioBet-793ZP) (CAT#: BioBet-793ZP)
Anti-ECSCR Antibody, Non-Fucosylated (BioBet-794ZP) (CAT#: BioBet-794ZP)
Anti-ECSCR Antibody, Non-Fucosylated (BioBet-796ZP) (CAT#: BioBet-796ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.